ID: ALA537421

Max Phase: Preclinical

Molecular Formula: C21H21Cl3N4O4S

Molecular Weight: 495.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(NS(=O)(=O)c2cc(Cl)ccc2Cl)c(O)c1CC(=O)NCc1ccnc(N)c1.Cl

Standard InChI:  InChI=1S/C21H20Cl2N4O4S.ClH/c1-12-2-5-17(27-32(30,31)18-9-14(22)3-4-16(18)23)21(29)15(12)10-20(28)26-11-13-6-7-25-19(24)8-13;/h2-9,27,29H,10-11H2,1H3,(H2,24,25)(H,26,28);1H

Standard InChI Key:  IVZXTUZMLCUSEE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 495.39

Molecular Weight (Monoisotopic): 494.0582

AlogP: 3.64

#Rotatable Bonds: 7

Polar Surface Area: 134.41

Molecular Species: ACID

HBA: 6

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.48

CX Basic pKa: 7.75

CX LogP: 2.69

CX LogD: 2.74

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.37

Np Likeness Score: -1.25

References

1. Hanessian S, Therrien E, van Otterlo WA, Bayrakdarian M, Nilsson I, Fjellström O, Xue Y..  (2006)  Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.,  16  (4): [PMID:16290930] [10.1016/j.bmcl.2005.10.082]

Source

Source(1):

• Scientific Literature